Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : Adrenocortical tumors
Participants in this research study have been diagnosed with a rare and aggressive type of cancer in the adrenal gland that is located next to one of the kidneys. This type of cancerous tumor is known as adrenocortical tumor or ACT.
There is no well accepted standard treatment for adrenocortical tumors due to their rare occurrence. Surgery to remove the cancer is the most common treatment. Surgery does not always remove all of the cancer and it can return. This often occurs when the disease has advanced at the time of diagnosis and the surgery to remove the cancer cannot be performed. When the disease has reached this stage, the treatment includes chemotherapy (anticancer drugs).
There are three possible treatment plans in this study. The treatment plans are based on the stage of the disease. Stages are assigned according to how advanced the disease is, the size of the tumor, and whether the disease has spread.
ACT in children are very commonly associated to the presence of a mutation in the p53 gene. This gene is very important for the normal growth and development of all the cells in the body and protects them from damage. Changes in this gene may cause cells to become cancerous and have been linked to adrenocortical tumors. Children that are born with a defective (mutated) gene have an increased risk of developing cancers, and the ACT are very common. In many instances, other family members have the same defective gene. For this reason, participants in this research study will be asked to donate a blood sample before starting treatment. This blood sample will be used to study the p53 gene. This is a voluntary part of the research study. Participants may decide not to participate in this part of the study and still be included in the treatment plan of the study.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Catherine Lam, MD, MPH
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.